Three years after approval, court blocks US launch of Enbrel biosimilarSandoz is to appeal a court decision preventing it from launching a cheaper biosimilar competitor to Amgen’s Enbrel Share XThree years after approval, court blocks US launch of Enbrel biosimilarhttps://pharmaphorum.com/news/three-years-after-approval-court-blocks-us-launch-of-enbrel-biosimilar/
Gilead invests $5.1bn in Belgian biotech GalapagosBelgian biotech Galapagos has signed a shiny new deal with Gilead to develop inflammatory disease and rheumatoid arthritis Share XGilead invests $5.1bn in Belgian biotech Galapagoshttps://pharmaphorum.com/news/gilead-invests-5-1bn-in-belgian-biotech-galapagos/
EU regulators slap safety restriction on Pfizer’s XeljanzEuropean safety regulators have placed restrictions on Pfizer’s Xeljanz, saying it should not be used in the higher Share XEU regulators slap safety restriction on Pfizer’s Xeljanzhttps://pharmaphorum.com/news/eu-regulators-slap-safety-restriction-on-pfizers-xeljanz/
J&J unveils top pipeline prospects, with main focus on cancerJohnson & Johnson has shone the spotlight on the most promising drugs in its pipeline, saying it plans Share XJ&J unveils top pipeline prospects, with main focus on cancerhttps://pharmaphorum.com/news/jj-unveils-top-pipeline-prospects-cancer/
AbbVie’s psoriasis drug Skyrizi approved in JapanAbbVie’s hotly anticipated psoriasis drug Skyrizi (risankizumab) has been approved in Japan, the first country to okay this Share XAbbVie’s psoriasis drug Skyrizi approved in Japanhttps://pharmaphorum.com/news/abbvies-psoriasis-drug-skyrizi-approved-in-japan/
Genentech buys NASH biotech JecureRoche’s Genentech unit has bought California biotech Jecure Therapeutics, which is researching drugs that could be used in Share XGenentech buys NASH biotech Jecurehttps://pharmaphorum.com/news/genentech-buys-nash-biotech-jecure/
NHS saving £300m with Humira biosimilar dealThe NHS is to save £300 million after striking deals with several manufacturers of low cost biosimilars of Share XNHS saving £300m with Humira biosimilar dealhttps://pharmaphorum.com/news/nhs-saving-300m-with-humira-biosimilar-deal/
Samsung Bioepis’ Humira biosimilar launches in EUSamsung Bioepis has become the latest biosimilars company to confirm it has launched a cheaper near-copy of AbbVie’s Share XSamsung Bioepis’ Humira biosimilar launches in EUhttps://pharmaphorum.com/news/samsung-bioepis-humira-biosimilar-launches-in-eu/
Billions up for grabs as EU patent on AbbVie’s Humira expiresThe patent for Humira, the world’s bestselling drug, expires in Europe today – opening the door for a Share XBillions up for grabs as EU patent on AbbVie’s Humira expireshttps://pharmaphorum.com/news/billions-up-for-grabs-as-eu-patent-abbvies-humira-expires/
